BeiGene has appointed Giancarlo Benelli at its Senior Vice President and Head of Europe.
Mr Benelli has more than 20 years of experience in the pharmaceutical space, holding positions at key businesses such as Novartis and AstraZeneca.
Most recently, Giancarlo was appointed as the VP and Head of Radioligand Therapy for international markets at Novartis.
He has also served as the General Manager at Advanced Accelerators Applications, where he was responsible for the restructuring of manufacturing and R&D in Adacap, which was recently acquired by Novartis.
Giancarlo's main goal at BeiGene will be to grow the company's global presence — with a specific focus on the key European market.
In addition to Mr Benelli's appointment, BeiGene has considered a name change, with the proposed new name being BeOne Medicines.
The company has not yet commented on when this may take place.
Co-Founder and CEO of BeiGene, John Oyler, commented: “We are pleased to welcome Giancarlo to BeiGene in what continues to be a transformative journey for us, solidifying our position as a top global oncology innovator. Giancarlo brings a wealth of experience and a proven track record in the pharmaceutical industry, which will be instrumental as we continue to grow our presence in Europe led from our office in Basel, Switzerland."
"His leadership and vision are a perfect fit for BeiGene, aligning with our commitment to expanding our global footprint and enhancing our capabilities in this vital region. We look forward to the positive impact his expertise will bring to our team and our work,"
"I am honoured and excited to join BeiGene at such a pivotal point in the Company’s growth,” said Mr. Benelli.
"BeiGene's dedication to discovering and developing innovative treatments that are both affordable and accessible resonates deeply with my own personal and professional values. I am eager to connect with more than 800 of our colleagues across Europe to contribute to our shared aspiration of transforming the lives of cancer patients. Together, we will strive to expand our reach and impact in Europe, bringing hope and healing to those who need it most."